How Often Do We Face Side Effects of Sirolimus in Pediatric Renal Transplantation?

• Published in: Transplantation proceedings Vol. 45; no. 1; pp. 185 - 189
• Main Authors: Fidan, K, Kandur, Y, Sozen, H, Gonul, İ.I, Dalgic, A, Söylemezoğlu, O
• Format: Journal Article
• Language: English
• Published: United States Elsevier Inc 2013
• Subjects: Adolescent; Child; Cholesterol - metabolism; Creatinine - blood; Female; Glomerular Filtration Rate; Graft Survival; Humans; Immunosuppressive Agents - adverse effects; Immunosuppressive Agents - therapeutic use; Kidney - pathology; Kidney Failure, Chronic - complications; Kidney Failure, Chronic - drug therapy; Kidney Failure, Chronic - surgery; Kidney Transplantation - methods; Living Donors; Male; Sirolimus - adverse effects; Sirolimus - therapeutic use; Steroids - therapeutic use; Surgery; Time Factors; Tissue Donors; Treatment Outcome; Triglycerides - metabolism; Young Adult
• ISSN: 0041-1345; 1873-2623
• DOI: 10.1016/j.transproceed.2012.08.005

Abstract We analyzed 25 pediatric renal transplantation patients on sirolimus (SRL) therapy to assess changes in serum creatinine, glomerular filtration rate, electrolytes, triglycerides, cholesterol, and side effects. Mean time to initiate SRL therapy was 3.2 years. The serum creatinine levels of patients on SRL treatment at 1, 6, 12, and 24 months were 1.67 ± 1.15 mg/dL, 1.18 ± 0.52 mg/dL, 1.24 ± 0.32 mg/dL, 1.15 ± 0.31 mg/dL, and 1.17 ± 0.12 mg/dL, respectively. We observed proteinuria in 3, hyperlipidemia in 5, and anemia in 2 patients, but none had the treatment discontinued. We diagnosed interstitial pneumonia in (n = 1), nasal acneiform lesions (n = 1), and lower extremity edema (n = 1). Hypokalemia developed in 1 subject with high blood SRL levels. In the follow-up period there was no case of acute rejection episode during SRL therapy.